February 15, 2017 / 12:59 AM / 7 months ago

BRIEF-Gilead announces 144-week data evaluating safety and efficacy of Genvoya

Feb 14 (Reuters) - Gilead Sciences Inc :

* Gilead announces 144-week data evaluating safety and efficacy of Genvoya for treatment of HIV-1 in treatment-naïve adults

* Gilead Sciences-Genvoya showed higher virologic suppression versus co’s stribild based on percentage of patients with HIV-1 RNA levels less than 50 copies/ml Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below